Altered distribution of mucosal NK cells during HIV infection. by Sips, M et al.
UCSF
UC San Francisco Previously Published Works
Title
Altered distribution of mucosal NK cells during HIV infection.
Permalink
https://escholarship.org/uc/item/6hq6b5sx
Journal
Mucosal immunology, 5(1)
ISSN
1933-0219
Authors
Sips, M
Sciaranghella, G
Diefenbach, T
et al.
Publication Date
2012
DOI
10.1038/mi.2011.40
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Altered distribution of mucosal NK cells during HIV infection
Magdalena Sips1, Gaia Sciaranghella1, Thomas Diefenbach1, Anne-Sophie Dugast1, 
Christoph T. Berger1, Qingquan Liu1, Douglas Kwon1, Musie Ghebremichael1, Jacob D. 
Estes2, Mary Carrington1,3, Jeffrey N. Martin4, Steven G. Deeks4, Peter W. Hunt4, and Galit 
Alter1
1Ragon Institute of Massachusetts General Hospital, Harvard University and Massachusetts 
Institute of Technology (former known as Partners AIDS Research Center of Massachusetts 
General Hospital) Boston, MA, USA
2AIDS and Cancer Virus Program, Frederick Inc., National Cancer Institute, Frederick, Maryland, 
USA
3Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, 
Inc., NCI-Frederick, Frederick, MD 21702, USA
4University of California, San Francisco, Positive Health Program, San Francisco, 94110, USA
Abstract
The human gut mucosa is a major site of HIV infection and infection-associated pathogenesis. 
Increasing evidence shows that natural killer (NK) cells play an important role in control of HIV 
infection but the mechanism(s) by which they mediate antiviral activity in the gut is unclear. Here 
we show two distinct subsets of NK cells exist in the gut, one localized to intraepithelial spaces 
(IEL) and the other to the lamina propria (LP). The frequency of both subsets of NK cells was 
reduced in chronic infection, whereas IEL NK cells remained stable in spontaneous controllers 
with protective KIR/HLA genotypes. Both IEL and LP NK cells were significantly expanded in 
immunologic non-responsive (INR) patients, who incompletely recovered CD4+ T cells on 
HAART. These data suggest that both IEL and LP NK cells may expand in the gut in an effort to 
compensate for compromised CD4+ T cell recovery, but that only IEL NK cells may be involved 
in providing durable control of HIV in the gut,
Introduction
Over the course of past decade, our understanding of HIV-pathogenesis has changed 
considerably, as we have begun to appreciate the role of the gastrointestinal (GI) tract in 
HIV-associated immunopathology1–3. Several lines of evidence suggest that HIV 
preferentially infects activated memory CD4+ T cells4, and therefore the gut, which harbors 
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a large concentration of activated memory CD4+ T cells, provides fertile ground for rapid 
HIV infection and dissemination. As early as the first few weeks of HIV infection, 
significant physical and immunological changes occur in the gut, including a massive 
accumulation of CD8+ T lymphocytes2,5,6 and a massive depletion of CD4+ T cells7. These 
dramatic changes in cell frequencies in the gut are accompanied by increased gut 
permeability resulting in microbial translocation, leading to elevated levels of microbial 
products in the blood such as lipopolysaccharide (LPS) that has been shown to contribute to 
the induction of immune activation8.
Despite the early burst of HIV replication in acute infection, in both blood and the gut, acute 
viral replication is brought down to a viral set-point that persists throughout chronic 
infection9. Given that HIV replicates robustly in the GI tract, it is likely that immune 
responses must work aggressively during acute infection in the gut to contain the ongoing 
dramatic viral replication. It is therefore plausible that these GI antiviral responses may 
represent the most robust control over the virus, and measurements of the immune response 
in the peripheral blood may not necessarily reflect responses in the gut.
Interestingly, epidemiologic and functional evidence suggest that NK cells play an important 
role in controlling AIDS progression10–12. Highly functional clonal populations of NK cells 
expand rapidly during acute HIV infection, prior to the induction of adaptive immune 
responses10,11 and particular killer immunoglobulin-like receptors (KIR), KIR3DS1 and 
KIR3DL1, that interact with a subclass of HLA-B alleles, called HLA-Bw4–80I, are 
associated with slower HIV-1 disease progression13,14. Thus increasing evidence points to 
an important role for NK cells in early and durable antiviral control; however, the 
mechanism(s) and location of their antiviral activity remains unknown.
NK cells are large granular lymphocytes that play a major role in elimination of both tumors 
and virally infected cells without the need for antigen sensitization15. Several lines of 
evidence suggest that dramatic changes occur within the NK cell compartment during HIV 
infection, including phenotypic and functional changes16–19 that potentially contribute to the 
failure to control infection and progression to AIDS20,21. However, NK cells in individuals 
expressing protective KIR/HLA genotypes expand rapidly in acute infection and exhibit 
strong antiviral activity against HIV in vitro14. Furthermore, recent studies from Vieillard et 
al. demonstrated that spontaneous HIV controllers exhibit robust NK cell responses22. Yet, 
given that the majority of HIV viral replication occurs in the gut, it is essential to define 
whether gut mucosal NK cells contribute to antiviral control at this vulnerable site of 
infection in these unique individuals that control HIV infection in the absence of therapy.
Early studies suggest that NK cells reside in the intra-epithelial space of the GI tract and in 
fact, NK cells have been identified as intra-epithelial lymphocytes (IEL) in various species 
of animals23–26 and humans27. In humans, gut NK cells, similar to uterine NK (uNK) cells, 
express high levels of CD56, KIR, and CD1628, produce proinflammatory cytokines (IFN-γ 
and TNF-α), and kill MHC negative target cells (K562 cells) in the presence of IL-2, IL-12, 
or IL-1529. Furthermore, gut NK cells have been shown to be crucially involved in 
controlling murine enteric coronaviral infections30. More recent data have documented a 
new subset of NK cells or lymphoid tissue inducers, the NK-22 cells, that secrete IL-22, 
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which is required for the maintenance of epithelium integrity31,32. Yet little is known about 
the distribution of NK cells in the human gut, and how these change during viral infections.
Here we sought to define whether durable control of HIV infection was associated with the 
preferential recruitment of NK cell populations to the gut, by analyzing rectosigmoid 
mucosal biopsies collected from patients at various stages of HIV infection. In our studies, 
we identified two distinct populations of gut mucosal-resident NK cells, one present in the 
IEL (IEL NK) and the other in the lamina propria (LP NK). Interestingly, we observed 
changes in IEL and LP NK cell frequencies in HIV infection. Unexpectedly, increased 
frequencies of both IEL and LP NK cells were only observed in subjects with incomplete 
peripheral blood CD4+ T cell recovery (CD4<350 cells/ul) despite long-term antiretroviral 
therapy (ART)-mediated viral suppression. However importantly, spontaneous controllers 
expressing protective KIR/HLA genotypes had higher IEL NK cell numbers than those with 
non-protective genotypes, suggesting that IEL NK cells may contribute to durable control of 
HIV in these individuals. These data suggest that two subsets of NK cells exist in the human 
gastrointestinal tract, one in the IEL and one in the LP, one of which may be involved in 
durable control of HIV infection, and both that may expand at this vulnerable site in 
response to incomplete immune recovery following virologic suppression.
Results
GI tract CD3negNKp46pos NK cells are localized within the intraepithelial space and lamina 
propria
Epidemiologic data suggest that NK cells may play a critical role in controlling HIV-1 
infection13, however the majority of studies have focused on NK cells in the blood, whereas 
the virus replicates most profusely in the gut3. While several reports suggest that NK cells 
can be detected in gut mucosa in animals23–26,33–35, less is known about NK cells in human 
gut. Thus to define the frequency of NK cells in the gut, as well as their distribution and 
localization, immunohistochemistry (IHC) was used to visualize and quantify these cells. 
Traditionally, NK cells are defined as CD3negCD56pos/negCD16pos/neg, however this 
combination of markers is difficult to use in immunohistochemical staining, due to the fact 
that CD56 also stains neural tissue that is abundant in the GI tract. In contrast, specific 
family of receptors, the natural cytotoxicity receptors (NCRs), are thought to be exclusively 
expressed on NK cells36. Thus, NKp46, an NCR expressed on nearly all NK cells, was 
selected. Two NKp46 antibodies were used in the study to detect NK cells in human colon: 
polyclonal goat anti-human (GAH) NKp46 and monoclonal mouse anti-human (MAH) 
NKp46. Unexpectedly, these two antibodies labeled two distinct cell populations in the gut. 
The GAH NKp46 exclusively labeled cells located in intraepithelial spaces (IEL NK) (Fig. 
1A, 1C), whereas MAH NKp46 labeled lamina propria cells (LP NK) (Fig. 1B, 1D). LP NK 
cells were located in basolateral part of mucosa and within gut submucosa. Neither of these 
antibodies labeled cells within lymphoid aggregates, suggesting that NK cells may be 
excluded from inductive sites in the gut (data not shown). Additionally, a subset of IEL NK 
cells (Fig. 2A), but not LP NK cells (Fig. 2B), co-expressed CD57, a marker of terminal 
differentiation, present on NK cells and T cells37, suggesting that these two NK cell subsets 
represent phenotypically, and potentially functionally distinct cell types. Thus two 
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populations of NK cells were identified in healthy human gut, located in distinct regions of 
the tissues, potentially reflecting unique functional characteristics.
Confirmation of NKp46 antibody specificity
Having identified two populations of NK cells in the gut stained with different NKp46 
antibodies, we next sought to confirm that these IHC antibodies labeled NK cells in other 
tissues as well. We investigated whether these antibodies recognized NK cells in uterine 
tissue, known to be abundant in NK cells38. Abundant levels of NKp46+ cells were 
identified in healthy endometrial tissues with both GAH and MAH NKp46 antibodies (Fig. 
3A, 3B), suggesting that these antibodies did in fact recognize NK cells at other mucosal 
sites.
To further confirm that NKp46 antibodies labeled CD3neg cells, we performed a double 
staining by IHC and multi color IF to simultaneously label CD3pos and NKp46pos cells. 
Neither of the NKp46pos cell subsets stained positively with the CD3 antibody confirming 
that neither the IEL nor LP NK cells belong to the T cell lineage (Fig. 1C, 1D, 2A, 2B).
To ultimately validate that these NKp46 antibodies labeled NK cells specifically, both 
NKp46 antibodies were tested by flow cytometry and compared to the standard BD NKp46 
antibody (clone 9E2) widely used to stain peripheral blood NK cells. Both the GAH and 
MAH NKp46 stained similar frequencies of CD3negCD56pos/negCD16pos/neg blood NK cells 
as did the traditional BD antibody (Fig. 4A). Moreover, these antibodies did not label other 
cell subsets (data not shown). To further confirm the specificity of these antibodies for NK 
cells, NK cells were also costained with a range of additional NK cell markers, including 
NKp30, NKG2A, KIR and NKG2D (Fig. 4A), demonstrating that both GAH and MAH 
NKp46 antibodies labeled similar frequencies of NK cells bearing these other phenotypic 
markers.
Finally, to confirm that the GAH and MAH NKp46 antibodies stain mucosal NK cells, 
freshly collected-enzymatically digested gut tissue was stained with the two antibodies and 
frequencies of NK cells were compared with the traditional BD antibody NK cell 
frequencies. All three NKp46 antibodies labeled CD45posCD3neg lymphocytes isolated from 
the gut (Fig. 4B), that also coexpressed CD56 and CD16 (data not shown). However, 
interestingly, the three antibodies labeled different frequencies and intensities of CD56pos 
NK cells, in such a way that the MAH labeled more CD56bright NK cells than the GAH 
NKp46 antibody, suggesting some differences in NK cell subset specificity in the gut. 
Furthermore, all three antibodies stained CD45posCD3negNKp46pos cells that also co-
expressed NKG2A, confirming that the stained mucosal cells belong to the NK cell lineage 
(Fig. 4B). Thus overall, these data suggest that both NKp46 antibodies, used to detect NK 
cells in the gut, are highly specific for NK cells.
No alteration in the IEL:LP NK cell balance during HIV infection
Given the fact that the two NKp46 antibodies labeled two distinct NK cell populations in the 
gut, we next sought to determine if HIV infection is associated with differential recruitment 
of either of these NK cell subsets to this vulnerable site, where they may play a role in 
antiviral control. Slides from colon biopsies were collected from 65 subjects, including 15 
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HIV negative individuals and 50 HIV positive patients with differential control of HIV 
infection: 20 untreated controllers (11-elite controllers: <75 RNA copies/ml and 9-viremic 
controllers: 75–2000 RNA copies/ml), 9 chronic untreated patients (<2000 RNA copies/ml) 
and 21 treated patients (11 with optimal CD4+ T cells recovery and 10 with suboptimal 
recovery: all <75 RNA copies/ml). Slides were stained with the GAH and MAH NKp46 
antibodies and the frequencies of IEL and LP NK cells were counted manually in whole 
tissue scans. Patients were grouped into HIV negative controls and HIV-infected individuals 
for initial studies.
In healthy controls IEL NK cells were more frequent than LP NK cells (Fig. 5A). Despite 
the presence of both of these subsets of NK cells in the gut, there was no relationship 
between the frequency of each subset in the gut of healthy individuals (Fig. 5C), suggesting 
that they may be recruited independently to these sites. Interestingly, while the ratio of 
IEL:LP NK cells was preserved in HIV infection (Fig. 5B), a positive correlation was 
observed between these two NK cell populations in HIV+ subjects (Fig. 5D), suggesting that 
in HIV infection these cells may be synergistically recruited to the gut, to contribute to 
immune control. These data suggest that under homeostatic conditions, the frequency of the 
IEL and LP NK cells is unrelated, but during infection the recruitment/expansion of these 
cells in the gut may occur in a coordinated manner.
Expansion of NK cells in immunologically non-reconstituted patients after HAART
Given the alteration in the relationship between IEL and LP NK cells in HIV infection, we 
were intrigued to next define whether these cells were specifically expanding/accumulating 
in specific HIV-infected patient populations. We hypothesized that both of these NK cell 
subsets would expand preferentially in the controller group, potentially contributing to 
durable control of HIV infection, whereas we speculated that the frequency of these cells 
would be depressed in chronically infected individuals off therapy. As expected, we 
observed a trend towards a decrease in the frequency of both IEL and LP NK cells in 
chronic untreated patients with high viral loads (VL) as compared to HIV- subjects (Fig. 6A, 
6B). However, we observed a remarkably heterogeneous distribution of NK cells in 
controllers, marked by a wide distribution of both IEL and LP NK cell frequencies, with 
some individuals exhibiting some of the highest levels of both subsets of NK cells in their 
guts, whereas the vast majority exhibited some of the lowest frequencies of these cells. No 
difference was observed in either IEL or LP NK cell frequencies among elite compared to 
viremic controllers (Fig. 6C). Conversely, the most dramatic expansion of both IEL and LP 
NK cells was observed in the treated patient group that exhibited incomplete or suboptimal 
CD4+ T cell recovery despite long-term anti-retroviral therapy, (immunological non-
responders (INR)) (ART INR:CHRO UNTX P<0.05 for both IEL and LP NK cells, Fig. 6A, 
6B). LP NK cells in immunologic non-responders were also significantly more frequent 
compared to LP NK cells in spontaneous controllers (ART INR:CONTRL P<0.05). 
Interestingly, this expansion of IEL and LP NK cells in the INR patients was related (Fig. 
6D), and appeared to drive the IEL/LP NK cell correlation observed in Fig. 5D. These data 
suggest for the first time that NK cell distribution in the gut of controllers is quite 
heterogeneous, NK cell frequencies decline in chronic HIV infection, but that both IEL and 
LP NK cells expand in the GI tract of incompletely reconstituted HIV+ subjects on ART 
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suggesting that NK cells may accumulate in the absence of viral replication in this 
vulnerable mucosal tissue in response to incomplete immunologic reconstitution, to 
potentially provide a compensatory mechanism for the compromised immunity.
Positive correlation of gut IEL NK cells and CD4 T cells in periphery in chronic infection
Given that the absolute number of circulating CD4+ T cells and plasma viral set point serve 
as markers of disease progression, we were next interested in defining whether the 
frequencies of either of the two populations of NK cells in the gut of HIV-infected patients 
were related to changes with either of these 2 clinical parameters. We therefore compared 
the frequency of NK cells to the VL, CD4 and CD8 count in the peripheral circulation. We 
found no correlation between VL and NK cells in any of the patient populations, potentially 
suggesting that the peripheral level of viremia may not drive these changes in NK cell 
frequencies, but that perhaps local viral replication could have an impact. However, a 
positive correlation between IEL NK cells and peripheral blood CD4+ T cells (R2=0.3322, 
P=0.0498) and a negative correlation between IEL NK and peripheral blood CD8+ T cells 
(R2=0.4071, P=0.0256) was observed in untreated, chronically infected patients (Fig. 6D). 
These data show that the inversion of the CD4:CD8 ratio, associated with inflammation, 
may potentially reflect a dampening of the NK cell response in the setting of an increase in 
CD8+ T cell numbers, as has been previously shown in acute HIV infection11.
Higher frequency of IEL NK cells in spontaneous controllers with protective KIR/HLA 
genotypes
Previous epidemiologic studies have shown that particular KIR/HLA compound genotypes 
are associated with spontaneous control of HIV13,39. Given the wide variation in NK cell 
frequencies in spontaneous controllers (Fig. 6A and 6B), unrelated to the degree of antiviral 
control (Fig. 6C), we next sought to determine whether these protective KIR/HLA 
genotypes may account for differences in NK cell frequencies in the gut in spontaneous 
controllers. Thus, ECs and VCs were genotyped for KIR and HLA, and were grouped into 
those with protective genotypes (KIR3DS1 or KIR3DL1 *001, *002, *008, *015 and *009 
in combination with HLA-Bw4 alleles with an isoleucine at position 80) and those without 
protective genotypes (the rest). Interestingly, there was a trend towards significantly higher 
frequencies of IEL NK cells detected in controllers with protective KIR/HLA compound 
genotypes (p=0.0549) but not in LP NK cells (Fig. 7). These data support a potential role for 
a persistent expansion of protective IEL NK cell populations in the gut mucosa in 
spontaneous controllers that may directly contribute to durable control of viral replication at 
this vulnerable site beyond acute infection.
Discussion
Based on our recent understanding of the role of the gut as the primary site of HIV viral 
replication, we sought to define whether NK cells, a subset of innate immune cells, may 
accumulate preferentially at this site in individuals that progress more slowly to disease. In 
our study we identified two populations of NK cells in the GI tract, one that resides in 
intraepithelial space of the crypts (IEL NK) and one present in the lamina propria (LP NK) 
of the colon tissue (Fig. 1). Furthermore, we observed a remarkable heterogeneity in the 
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distribution of IEL and LP NK cells in spontaneous controllers, where some of these patients 
expressed the highest frequencies of NK cells in the gut, but the majority exhibited reduced 
frequencies of these innate immune cells, similar to the levels observed in chronic HIV 
infection. Moreover, we observed that the frequency of both IEL and LP NK cells were 
expanded in HAART treated patients that did not fully reconstitute their CD4+ T cell 
numbers (Fig. 6A, 6B). Additionally, IEL NK cells were preserved in spontaneous 
controllers with protective KIR/HLA genotypes compared to controllers with non-protective 
KIR/HLA genetic backgrounds. These data suggest for the first time that IEL NK cells may 
contribute to persistent durable control of viral replication in the gut in controllers with 
protective KIR/HLA compound genotypes, and that both IEL and LP NK cells expand at 
this vulnerable site in individuals that are incompletely able to recover from the assault of 
the virus, potentially in an effort to compensate for the persisting compromised environment 
within this barrier.
It is incompletely understood what contributes to the lack of immunologic reconstitution. 
Some recent data show that collagen deposition and disruption of the lymphatic tissue 
architecture contribute to persistent CD4+ T cell depletion prior to treatment, and the extent 
of these changes affects the efficiency of immune reconstitution after the initiation of 
therapy41. Such observations have been made at first in lymph nodes (LN)41 and 
subsequently in gut-associated lymphatic tissue (GALT)42, the latter suffering from a more 
pronounced loss in CD4+ T cell numbers3,43–45. Furthermore, immunological non-
responders exhibit particular unique clinical characteristics including fibrosis in LNs and gut 
tissue, increased persistent immune activation, and elevated markers of chronic 
inflammation despite undetectable VLs46. Thus despite the direct-antiretroviral effects on 
reducing viral replication, these individuals still exhibit some markers of chronic disease. In 
addition to these markers of continued disease pathology, we report here that these 
individuals also exhibit a remarkable expansion of NK cells in the gut (Fig. 6A, 6B). We 
speculate that incomplete immunological reconstitution causes some additional 
inflammatory stimuli in the gut, potentially due to some persistent low level viral 
replication, resulting in the persistent recruitment of innate immune cells to help provide 
some level of protection in the absence of CD4+ T cells. Thus mucosal NK cells may 
expand in an effort to compensate for the compromised gut mucosal immunity. 
Interestingly, this NK cell expansion is not observed in chronic untreated patients, despite 
the fact that they exhibit reduced CD4+ T cell numbers as well, however, these individuals 
also exhibit high levels of viral replication and persistent immune activation, due to 
microbial translocation8, through accessory cells40. This hyper-activation, however, may 
drive direct NK cell apoptosis47, thereby preventing the observed increase of these cytolytic 
effector cells within tissues.
Epidemiologic work strongly suggests that NK cells may be directly involved in antiviral 
control of HIV10,13,14. We therefore speculated that these innate effectors may expand 
preferentially in the gut of individuals that exhibit durable control of HIV, including the elite 
and viremic controllers. Overall controllers exhibited a heterogeneous distribution of both 
IEL and LP NK cells in mucosal sections (Fig. 6A and B), that did not differ in ECs or VCs 
(Fig. 6C), and were similar in overall numbers from that seen in chronically infected 
individuals. However, given the strong epidemiologic data suggesting that specific 
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KIR/HLA combinations contribute to spontaneous control of HIV infection, we examined 
IEL and LP NK cell distributions among controllers with protective and non-protective 
KIR/HLA genotypes. Interestingly, we observed a trend towards a elevated IEL, but not LP, 
NK cells in controllers with protective KIR/HLA genotypes, suggesting for the first time 
that particular NK cell populations may persist in these unique individuals at this vulnerable 
site, aimed at maintaining long-term control of HIV infection. The specific preservation of 
IEL, and not LP, NK cells may reflect functional differences between these subsets of 
lymphocytes. Previous work has suggested that lymphocytes able to traffic in the IEL 
exhibit more cytolytic functional properties than those found in the LP48. This may suggest 
that the elevated IEL NK cells in controllers with protective KIR/HLA genotypes may 
confer an enhanced capacity to rapidly deploy the cytolytic antiviral activity of NK cells, 
should the cell encounter a potential viral burst that have been suggested to occur in some 
controllers49. However, additional in depth functional studies are required to begin to dissect 
the functional and phenotypic properties of NK cells in these two compartments of the 
tissues, and particularly those that may expand in spontaneous control in the setting of 
protective KIR/HLA genotypes.
Early studies from animal models have shown IEL lymphocytes to have higher cytolytic 
activity than LP48 or Peyer’s patches lymphocytes35, however the specific distribution and 
functional properties of NK cells in the gut have been poorly explored. A population of 
cells, called NK-22, was reported to reside in the lamina propria of tonsils, lacking classical 
markers (including NKp46) of NK cells, but expressing NKp44 and secreting IL-22 required 
for the maintenance of epithelium integrity31. Yet, several lines of evidence now suggest 
that NK-22 cells belong to a subset of lymphoid-tissue inducer (LTi) cells, rather than 
conventional NK cells32. However, here we report the presence of two NK cell subsets, 
distinct from NK-22 as they express NKp46, that are distributed in distinct effector 
compartments of the gut. Based on their location within mucosa, we speculate that IEL NK 
cells may be more cytolytic and may serve as the first line of defense, just beneath the 
epithelial border, whereas LP NK cells, located in basolateral surface of gut mucosa and in 
submucosa may constitute an immunoregulatory type of NK subset, similar to that seen in 
the uterine tissues. These two NK cell subsets exhibit distinct phenotypes what supports this 
potential functional difference, as only IEL NK cells co-express the terminal differentiation 
marker CD57 (Fig. 2) that is expressed on more cytolytic blood NK cells37. The fact that 
these two NK cell populations were identified by two antibodies targeting the same antigen 
mounted in different species, suggests that the NKp46 receptor may exhibit conformational 
changes depending on the activation status of NK cells. A similar scenario has been 
observed for the CD43 molecule, where two distinct antibodies recognize differentially 
glycosylated isoforms of the receptor, reflecting distinct activation states of the lymphocytes 
on which they are expressed50. Given that NKp46 is highly glycosylated51, we speculate 
that these two antibodies may recognize NKp46 antigens with unique glycosylation patterns 
or conformational changes on IEL and LP NK cells, providing a useful mechanism by which 
to identify mucosal NK cell subpopulations.
In summary, our data demonstrate that two distinct populations of NK cells reside in the gut 
and may represent two innate effector cell subsets with unique functional properties related 
to their tissue localization. We show that the frequency of both subsets of NK cells change 
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following HIV infection, with an overall loss of both subsets in chronic infection, but with a 
significant expansion in immunologic non-responders. Furthermore, we show that the 
protective KIR/HLA genotypes are associated with a preservation of IEL NK cells in 
spontaneous controllers. These data suggest that while chronic HIV infection is associated 
with reduced frequencies of these innate effector cells in the gut, these cells respond robustly 
and expand in the setting of incomplete immune reconstitution potentially aimed at 
compensating for incomplete immunological recovery in patients on HAART and in 
spontaneous controllers with protective KIR/HLA genotypes what may provide durable 
protection from infection following acute infection.
Materials and methods
Subjects
Formalin-fixed-paraffin-embedded (FFPE) tissue slides from rectosigmoid mucosal biopsies 
from a total of 65 individuals from the SCOPE cohort were used in this study, among which 
50 were HIV-infected patients and 15 were uninfected healthy controls. HIV-infected 
samples included 20 untreated HIV spontaneous controllers, that spontaneously control HIV 
viral replication in the absence of therapy (11 ‘Elite Controllers’ with viral load (VL)<75 
copies/ml and 9 ‘Viremic Controllers’ with VL 75–2000 copies/ml); 9 untreated non-
controllers (‘Chronic untreated’), that remained off-therapy during infection with VL>2000 
copies/ml (most with VL>10000 copies/ml); 21 treated patients on antiretroviral therapy 
with VL<75 copies/ml (11 ‘Immunologic responders’ (IRs) with optimal CD4 recovery>500 
cells/mm3 of blood; and 10 ‘Immunologic non-responders’ (INRs) with suboptimal CD4+ T 
cell recovery <350 cells/mm3). IRs and INRs maintained ART-mediated viral suppression 
for a median of 8.2 years and 4.4 years, respectively. Detectable episodes of viremia <500 
copies/ml were allowed during these intervals if preceded and followed by undetectable 
values. In addition to having lower CD4+ T cell counts at the time of the rectal biopsy (<350 
cells/mm3 vs. >500 cells/mm3), INRs also had a lower median rate of CD4+ T cell recovery 
in the two years prior to the rectal biopsy (+11.9, IQR: +8.2 to +15.2 CD4+ T cells/mm3 per 
year) than the IRs (+24.8, IQR: +18.3 to +36.7 CD4+ T cells/mm3 per year, P=0.002 for 
between group comparison). Laboratory personnel were blinded to HIV disease status until 
measurements were completed.
KIR/HLA genotyping
We performed genotyping of the HLA locus following the PCR-SSOP (sequence-specific 
oligonucleotide probing) typing protocol recommended by the 13th International 
Histocompatibility Workshop (http://www.ihwg.org/components/ssopr.htm). For 
KIR3DL1/S1 subtyping, polymorphic exons 3, 4, 5, 7, 8 and 9 were selectively amplified in 
four PCR reactions using locus-specific primers (a separate PCR for each of exons 3, 4 and 
5, and a fourth PCR for exons 7, 8 and 9 combined). The PCR products were blotted on 
nylon membranes and hybridized with a panel of 56 sequence-specific oligonucleotide 
(SSO) probes designed to detect unique sequence motifs of known KIR3DL1 alleles. 
KIR3DL1 alleles were assigned by the reaction patterns of the SSO probes based on the 
known KIR3DL1 sequences, as previously described39. Ambiguous SSO typing results were 
resolved by sequencing analysis.
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Immunohistochemistry (IHC)
FFPE slides were de-paraffinized and hydrated. Antigen retrieval was performed in 
Deckloaking Chamber (Biocare medical), inducing temperature of 125°C and pressure of 25 
psi. Endogenous peroxidase activity was blocked with buffered hydrogen peroxide (Biocare 
medical) for 5 mins at room temperature (RT). Unspecific binding of antibodies (Abs) was 
blocked using purified casein and other proteins (Background Sniper, Biocare medical) for 
10 mins in RT and donkey serum (Sigma) for 15 mins. Slides were incubated with the 
following primary Ab for 1h at RT: mouse monoclonal anti-human NKp46 (R&D), goat 
polyclonal anti-human NKp46 (R&D), rabbit polyclonal anti-human CD3 (DAKO), mouse 
monoclonal anti-human CD57 (DAKO). The following control Abs were used: mouse 
IgG2B Isotype Control (R&D), goat control Ab (R&D), mouse IgM Isotype Control 
(DAKO). EnVision+Systems-HRP (anti-mouse and anti-rabbit) or rabbit anti-goat-HRP Ab 
(DAKO) were used for 45 min at RT as a secondary Ab and visualization was performed 
with a diaminobenzidine (DAB+) substrate chromogen (DAKO). For double staining 
procedure, denaturing solution, AP conjugated secondary Abs and Vulcan Fast Red 
chromogen (Biocare medical) were used for the detection of the second antigen. Sections 
were counterstained with hematoxylin, dehydrated and mounted in mounting medium.
Immunofluorescence (IF)
De-paraffinization, hydration and antigen retrieval steps were performed as described in 
IHC section. Prior to incubation with the primary Ab, slides were immersed in 0.3% Sudan 
Black B in 70% ethanol for 2hrs at RT in order to mask autofluorescence present in tissues. 
Slides were blocked and incubated with primary or control Abs as described in IHC section. 
The following secondary Abs were used for detection of cells: donkey anti-mouse 
AlexaFluor 555 or A488 (Invitrogen), donkey anti-goat AlexaFluor A488 (Invitrogen), and 
donkey anti-rabbit AlexaFluor A647 (Invitrogen). Nuclei were stained with Hoechst 33258 
(Invitrogen). Slides were mounted with Gold ProLong antifade reagent (Invitrogen).
Microscopy
Slides were scanned with Zeiss MIRAX MIDI automated slide scanner in brightfield mode 
for IHC staining or fluorescence mode for IF staining. High quality, high magnification 
images were taken using Zeiss LSM510 laser scanning confocal microscope.
Image analysis
Cells were counted manually from 12 bit TIFF images acquired from whole tissue scans. 
The tissue area measurements were performed using ImageJ software (NIH, Bethesda, MD) 
and obtained frequencies of cells were presented as number of cells/mm2 of tissue.
Flow cytometry
Flow cytometric evaluation of NKp46 antibody staining was performed on peripheral blood 
mononuclear cells (PBMC) and freshly isolated lymphocytes from enzymatically digested 
gastrointestinal tissues. At least 106 PBMCs or gut lymphocytes were stained with anti-
CD3-PacificBlue, anti-CD16-APC-Cy7, anti-CD56-PE-Cy7 (BD Biosciences, San Jose, CA 
USA), anti-CD158a/anti-CD158b/anti-NKB1-FITC, anti-NKG2D-PE (BD Biosciences), 
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anti-NKG2A-Alexa Fluor 647 (Beckman Coulter, Fullerton, CA USA) and one of 3 NKp46 
antibodies followed by a secondary conjugated to Alexa Fluor 488 or Alexa Fluor 647. Cells 
were then washed and fixed by 4% paraformaldehyde, prior to acquisition on a BD LSRII. 
The expression of NKp46 was quantified on CD3negCD56pos/negCD16pos/neg lymphocytes 
using FlowJo, (Tree Star Inc., Ashland, OR USA). Additionally, CD45-Pe-Cy5.5 (BD 
Biosciences) and LIVE/DEAD stain (Invitrogen) were added for tissue lymphocyte staining 
and the expression of NKp46 was quantified on live, 
CD45posCD3negCD56pos/negCD16pos/neg lymphocytes.
Statistics
Statistical analyses for comparison of IEL and LP NK cells in healthy and infected groups 
were performed using a Mann Whitney U test. Comparison of protective and non-protective 
KIR/HLA compound genotypes in spontaneous controller group was performed using a 
Mann Whitney U test. Spearman rank correlation coefficient was used to examine the 
relationships between IEL and LP NK cell frequencies. Statistical comparisons of NK cell 
frequencies among patient groups were made using Kruskal-Wallis test. P-values of 
pairwise comparisons were adjusted by using Dunn’s method. Reported p-values are two 
sided and values<0.05 were considered significant.
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FIG.1. Two distinct subsets of gut NK cells exist in different regions of the human colon
Immunohistochemical (IHC) staining depicts IEL NK cells stained in brown with GAH 
NKp46 antibody (a) and LP NK cells stained in brown with MAH NKp46 antibody (b). To 
confirm that NKp46+ cells were not T cells, double staining IHC was performed with CD3 
in brown and GAH NKp46 (c) and MAH NKp46 (d) in red. All images are displayed at 
400x magnification.
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FIG.2. IEL, but not LP, NK cells express CD57
Multicolor confocal immunofluorescence images show co-expression of CD57 (white), a 
marker of differentiated NK cells, on a subset of IEL NK cells (a) defined as CD3-negative 
(red) and NKp46-positive (green). LP NK cells (b) showed no such co-expression of CD57. 
Both images are displayed at 630x magnification.
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FIG.3. NKp46 antibodies also stain NK cells in the uterus
Both the GAH (a) and MAH (b) NKp46 antibodies labeled NK cells (brown) in the 
endometrial section. All images are displayed at 200x magnification.
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FIG.4. Flow cytometric confirmation of NKp46 antibody specificity for NK cells in the 
peripheral blood
To confirm that the 2 NKp46 antibodies specifically stained NK cells, the specificity of the 
antibodies was verified by flow cytometry using a panel of NK cell specific antibodies. The 
overall frequency of CD3−CD16+/−CD56+/− NK cells stained with the traditional BD 
NKp46, the GAH NKp46, and the MAH NKp46 were similar. Additional NK cell markers, 
including NKp30, NKG2A, KIR, NKG2D were expressed at equivalent levels on blood NK 
cells labeled with the 3 different NKp46 antibodies (a). Furthermore, lymphocytes isolated 
from the gut tissue were stained with the traditional BD NKp46, the GAH NKp46 and the 
MAH NKp46 to confirm that these antibodies label CD45posCD3neg NK cells in mucosal 
samples (b).
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FIG.5. IEL NK cells are more abundant than LP NK cells in both healthy and HIV-infected 
populations
The total frequency of IEL and LP NK cells were counted per mm2 of colon tissue in 
healthy individuals, demonstrating that IEL NK cells are more abundant in the gut mucosa 
compared to LP NK cells ** P<0.01 (a). Similarly, IEL NK cells exceeded the frequency of 
LP NK cells in the colon tissue of HIV-infected individuals ** P < 0.01 (b). Furthermore, 
the relationship between IEL and LP NK cells was explored, demonstrating no visible 
correlation in cell frequencies in healthy individuals (c), but a significant correlation in HIV
+ patients (d).
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FIG.6. Frequency changes in IEL and LP NK cells in HIV+ patients with differential control of 
infection and healthy controls
The frequency of IEL (a) and LP (b) NK cells was compared among the different HIV+ 
patient populations, including spontaneous controllers (CONTRL-), chronic untreated 
patients (CHRO UNTX-), treated chronically infected patients that exhibited immunologic 
reconstitution following HAART (ART+ IR-), treated chronically infected patients that were 
immunologic non-responders (ART+ INR-), and healthy controls (HIV NEG-) * P<0.05. 
These data demonstrate the expansion of both IEL and LP NK cells in ART-INR patients. 
Furthermore, the frequency of IEL and LP NK cells were also compared among elite (EC) 
and viremic (VC) controllers (c). IEL and LP NK cells frequencies are correlated in the INR 
group (d). The relationship between the frequency of IEL NK cells and the percent CD4+ T 
cells (CD4 PCT) and the percent CD8+ T cells (CD8 PCT) in the periphery is illustrated in 
panel (e).
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FIG.7. Impact of KIR/HLA compound genotypes on the frequency of gut mucosal NK cells
The difference in numbers of IEL NK cells and LP NK cells was compared between 
controllers expressing protective KIR/HLA alleles (KIR3DS1-Bw4-80I or KIR3DL1*h-
Bw4-80I) with those not expressing protective KIR/HLA alleles.
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